GB201103762D0 - Means and methods for the treatment of neurodegenerative disorders - Google Patents
Means and methods for the treatment of neurodegenerative disordersInfo
- Publication number
- GB201103762D0 GB201103762D0 GB201103762A GB201103762A GB201103762D0 GB 201103762 D0 GB201103762 D0 GB 201103762D0 GB 201103762 A GB201103762 A GB 201103762A GB 201103762 A GB201103762 A GB 201103762A GB 201103762 D0 GB201103762 D0 GB 201103762D0
- Authority
- GB
- United Kingdom
- Prior art keywords
- treatment
- methods
- disease
- directed against
- neurodegenerative disorders
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Ceased
Links
- 208000015122 neurodegenerative disease Diseases 0.000 title abstract 3
- 108020004459 Small interfering RNA Proteins 0.000 abstract 2
- 206010002026 amyotrophic lateral sclerosis Diseases 0.000 abstract 2
- 230000004770 neurodegeneration Effects 0.000 abstract 2
- 208000024827 Alzheimer disease Diseases 0.000 abstract 1
- DQFBYFPFKXHELB-UHFFFAOYSA-N Chalcone Natural products C=1C=CC=CC=1C(=O)C=CC1=CC=CC=C1 DQFBYFPFKXHELB-UHFFFAOYSA-N 0.000 abstract 1
- 102100022629 Fructose-2,6-bisphosphatase Human genes 0.000 abstract 1
- 101000823463 Homo sapiens Fructose-2,6-bisphosphatase Proteins 0.000 abstract 1
- 208000012902 Nervous system disease Diseases 0.000 abstract 1
- 208000025966 Neurological disease Diseases 0.000 abstract 1
- 102100037248 Prolyl hydroxylase EGLN2 Human genes 0.000 abstract 1
- 101710170760 Prolyl hydroxylase EGLN2 Proteins 0.000 abstract 1
- -1 aza chalcones Chemical class 0.000 abstract 1
- 235000005513 chalcones Nutrition 0.000 abstract 1
- 201000010099 disease Diseases 0.000 abstract 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 1
- 230000006692 glycolytic flux Effects 0.000 abstract 1
- 239000003112 inhibitor Substances 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Organic Chemistry (AREA)
- Genetics & Genomics (AREA)
- General Health & Medical Sciences (AREA)
- Zoology (AREA)
- General Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biochemistry (AREA)
- Wood Science & Technology (AREA)
- Biomedical Technology (AREA)
- Molecular Biology (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Biotechnology (AREA)
- Virology (AREA)
- Physics & Mathematics (AREA)
- Biophysics (AREA)
- Plant Pathology (AREA)
- Microbiology (AREA)
Abstract
The present invention has found that inhibitors reducing the glycolytic flux can be used for treatment of neurodegenerative diseases such as Alzheimer's disease, Parkonson's disease and amyotrophic lateral sclerosis. In particular the invention provides constructs comprising siRNAs directed against PHD1 for the treatment of ALS and siRNA's directed against PFKFB3 for the treatment of neurodegenerative diseases. The invention also provides the use of a therapeutically effective amount of aza chalcones or a pharmaceutically acceptable salt thereof for the treatment of neurological diseases.
Priority Applications (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GB201103762A GB201103762D0 (en) | 2011-03-07 | 2011-03-07 | Means and methods for the treatment of neurodegenerative disorders |
| PCT/EP2012/053646 WO2012119949A1 (en) | 2011-03-04 | 2012-03-02 | Means and methods for the treatment of neurodegenerative disorders |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GB201103762A GB201103762D0 (en) | 2011-03-07 | 2011-03-07 | Means and methods for the treatment of neurodegenerative disorders |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| GB201103762D0 true GB201103762D0 (en) | 2011-04-20 |
Family
ID=43923244
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| GB201103762A Ceased GB201103762D0 (en) | 2011-03-04 | 2011-03-07 | Means and methods for the treatment of neurodegenerative disorders |
Country Status (2)
| Country | Link |
|---|---|
| GB (1) | GB201103762D0 (en) |
| WO (1) | WO2012119949A1 (en) |
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2015187934A1 (en) * | 2014-06-06 | 2015-12-10 | Cureveda, Llc | Functionalized hetroaryl enones exhibiting nrf2 activation and their method of use |
| WO2020080979A1 (en) * | 2018-10-15 | 2020-04-23 | Gero Discovery Limited Liability Company | Pfkfb3 inhibitors and their uses |
| AU2022277299A1 (en) * | 2021-05-16 | 2023-12-07 | Metanoia Bio Inc. | Methods and compositions for treating neurological conditions |
| AU2022306297A1 (en) | 2021-07-09 | 2024-02-08 | Plexium, Inc. | Aryl compounds and pharmaceutical compositions that modulate ikzf2 |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5023252A (en) | 1985-12-04 | 1991-06-11 | Conrex Pharmaceutical Corporation | Transdermal and trans-membrane delivery of drugs |
| US5011472A (en) | 1988-09-06 | 1991-04-30 | Brown University Research Foundation | Implantable delivery system for biological factors |
| WO2002081628A2 (en) | 2001-04-05 | 2002-10-17 | Ribozyme Pharmaceuticals, Incorporated | Modulation of gene expression associated with inflammation proliferation and neurite outgrowth, using nucleic acid based technologies |
| WO2005014815A1 (en) * | 2003-08-08 | 2005-02-17 | President And Fellows Of Harvard College | siRNA BASED METHODS FOR TREATING ALZHEIMER’S DISEASE |
| US8088385B2 (en) | 2007-06-18 | 2012-01-03 | University Of Louisville Research Foundation Inc. | PFKB3 inhibitor for the treatment of a proliferative cancer |
-
2011
- 2011-03-07 GB GB201103762A patent/GB201103762D0/en not_active Ceased
-
2012
- 2012-03-02 WO PCT/EP2012/053646 patent/WO2012119949A1/en not_active Ceased
Also Published As
| Publication number | Publication date |
|---|---|
| WO2012119949A1 (en) | 2012-09-13 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| SG194701A1 (en) | Anti-cd40 antibodies and methods of use | |
| NZ707086A (en) | Anti-cd40 antibodies and methods of use | |
| WO2012149478A3 (en) | Agents useful for treating friedreich's ataxia and other neurodegenerative diseases | |
| PH12015500832A1 (en) | Pyrimidine hydroxy amide compounds as protein deacetylase inhibitors and methods of use thereof | |
| WO2013061161A3 (en) | New combination therapies for treating neurological disorders | |
| GB2492487B (en) | Cannabinoids for use in the treatment of neurodegenerative diseases or disorders | |
| PH12015500879A1 (en) | Compositions and methods for treating proteinopathies | |
| MY161656A (en) | Therapeutic use of diaminophenothiazines | |
| TN2013000414A1 (en) | 4-amino-5-fluoro-3- [6- (4 -methylpiperazin- 1 - yl) - 1h - benzimidazol - 2 - yl] - 1h - quinoli n-2-one for use in the treatment of adenoid cystic carcinoma | |
| EA201891833A1 (en) | COMBINATION FOR THE TREATMENT OF AMIOTROPHIC SIDE SCLEROSIS OR RELATED DISEASES | |
| MY198422A (en) | Pharmaceutical compositions comprising epa and a cardiovascular agent and methods of using the same | |
| MX2009010407A (en) | Fluorinated derivatives of deferiprone. | |
| PH12015500664A1 (en) | Pharmaceutical combinations comprising dual angiopoietin-2/dll4 binders and anti-vegf-r agents | |
| MX2019001977A (en) | Methods and compositions for treating multiple sclerosis and related disorders. | |
| WO2012154695A3 (en) | Treatment of polycystic disease | |
| PH12014501140A1 (en) | Protective agent for keratoconjunctiva or suppressive agent for keratoconjunctival disorder | |
| WO2013087654A3 (en) | Methods for preventing or treating disorders by increasing bioavailability of iron and related pharmaceutical formulation | |
| PH12016501173A1 (en) | Quinazolin-thf-amines as pde1 inhibitors | |
| PH12016500903A1 (en) | Novel methods for treating neurodegenerative diseases | |
| GB201103762D0 (en) | Means and methods for the treatment of neurodegenerative disorders | |
| MX2013015347A (en) | Egfr targeted therapy. | |
| WO2014028397A3 (en) | Laquinimod for treatment of gaba mediated disorders | |
| MX343366B (en) | Nd2 peptides and methods of treating neurological disease. | |
| GB201112145D0 (en) | Means and methods for the treatment of pathological angiogenesis | |
| WO2010004031A3 (en) | Treatment of amyotrophic lateral sclerosis by nogo-a-antagonist |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| AT | Applications terminated before publication under section 16(1) |